View Cart (0 items)

Pharmaceutical

Merck agrees to $8.4 billion deal for antibiotics developer Cubist

Healthcare giant Merck & Co., Inc. is to acquire antibiotics specialist Cubist Pharmaceuticals, Inc. for $8.4 billion, the company announced on Monday.
Read More

Rise in asthma, COPD cases driving pulmonary drug delivery systems market

The global market revenue of pulmonary drug delivery systems is expected to increase at a compound annual growth rate (CAGR) of 8.9 percent over the period 2014-2019.
Read More

Healthy growth predicted for empty capsules market

Capsules are widely considered an efficient method of taking medication and health supplements, and their use is set to grow in the coming years.
Read More

Bristol-Myers Squibb to build new biologics manufacturing plant in Ireland

The new manufacturing facility will produce multiple therapies for the biopharmaceutical company's growing portfolio of approved and investigational biologic medicines in therapeutic areas including oncology, virology and immunoscience.
Read More

Allergan enters acquisition deal with Actavis

Botox maker Allergan, Inc. will be acquired by Actavis plc for $66 billion after fending off a hostile takeover bid by activist investor William Ackman and Valeant Pharmaceuticals International Inc.
Read More

New Eastman copolyester for medical products could allow faster processing

A styrene-free alternative to high-impact polystyrene (HIPS) for opaque medical packaging has been introduced by Eastman Chemical Company in the European market.
Read More

Banned drugs found in dietary supplements after recalls

New research suggests that more rigorous regulatory oversight is needed in the dietary supplements industry.
Read More

Bayer Healthcare closes Dihon acquisition, invests in Versant fund

Bayer HealthCare, part of German chemical and pharmaceutical group Bayer AG, has completed its acquisition of Chinese pharmaceutical company Dihon Pharmaceutical Group Co., Ltd.
Read More

GlaxoSmithKline plans stock market sale of minority stake in HIV treatment company

British pharmaceutical group GlaxoSmithKline plc (GSK) is planning to spin off a subsidiary that focuses on developing treatments for HIV.
Read More

Novartis to sell influenza vaccines business for $275 million

Healthcare company Novartis has entered into an agreement to sell its influenza vaccines unit for $275 million.
Read More